Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study
Primary Purpose
Colorectal Cancer
Status
Unknown status
Phase
Phase 3
Locations
Taiwan
Study Type
Interventional
Intervention
Verum acupuncture
Sponsored by
About this trial
This is an interventional prevention trial for Colorectal Cancer focused on measuring acupuncture, chemotherapy, peripheral neuropathy, randomized clinical trial, numbness
Eligibility Criteria
Inclusion Criteria:
- Patients were diagnosed as stage 3 colorectal cancer.
- Patients are going to receive Oxaliplatin based chemotherapy.
- Patients are willing to cooperate with physicians and completely receive chemotherapy.
- Patients are willing to receive acupuncture treatments and follow-up assessments.
- Adult volunteers with the ages of 20-70 years old.
- ECOG Performance Status of 0, 1, or 2
Exclusion Criteria:
- Current active treatments with chemotherapy, radiotherapy or tumor resection surgery in the past one month.
- Having chemotherapy with neuropathic agents including taxane, platinum, vinca alkaloid, bortezimab, or thalidomide in the past six months.
- Local infection at or near the acupuncture site is not suitable for acupuncture after physician examination.
- Concurrent use of other alternative medicines such as herbal agents, high dose vitamins and minerals.
- Known coagulopathy or taking anticoagulants.
- Platelets < 50000/ul.
- WBCs < 3000/ul.
- Active CNS disease
- Cardiac pacemaker.
- Psychological or behavior disorder such as Schizophrenia.
- Currently pregnant or breastfeeding women.
- History of diabetic neuropathy or neuropathy related to HIV.
- Previous acupuncture treatment for any indication within 30 days of enrollment.
- Current medications that could affect symptoms related to CIPN.
- Grade III lymphedema or more severe situation
Sites / Locations
- China Medical University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Verum acupuncture
Sham acupuncture
Arm Description
16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
Outcomes
Primary Outcome Measures
Change from Baseline in NCV at 48weeks.
Change from Baseline in Von frey filament test at 48weeks.
Secondary Outcome Measures
Change from Baseline in questionnaire - FACT/GOG-Ntx Subscale at 48weeks.
Change from Baseline in questionnaire - FACT-G at 48weeks.
Change from Baseline in questionnaire - Brief Pain Inventory Short Form at 48weeks.
Full Information
NCT ID
NCT02744274
First Posted
April 13, 2016
Last Updated
April 19, 2016
Sponsor
Tzu-Liang Chen
Collaborators
Research Center For Chinese Medicine and Acupuncture
1. Study Identification
Unique Protocol Identification Number
NCT02744274
Brief Title
Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study
Official Title
Randomized, Assessor- and Participant-blinded, Controlled, and Parallel-design Approach to Investigate Whether Acupuncture Can Prevent or Postpone the Occurrence of Peripheral Neuropathy and Improve Quality of Life.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Tzu-Liang Chen
Collaborators
Research Center For Chinese Medicine and Acupuncture
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this pilot study is to investigate the efficacy of acupuncture in prevention of chemotherapy induced peripheral neuropathy. The study adapted a single center, randomized, assessor- and participant-blinded, controlled, and parallel-design approach to investigate whether acupuncture can prevent or postpone the occurrence of peripheral neuropathy and improve quality of life.
Detailed Description
Background and purpose:
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect of several commonly used antineoplastic agents. CIPN prevalence was 68.1% within the first month of the end of chemotherapy, 60% at 3 months, and 30.0% at 6 months or later. Oxaliplatin as a chemotherapeutic drug for colorectal cancer has neurotoxicity on peripheral nerve system. A definite portion of patients suffered neurologic symptoms including paresthesia, dysesthesia over limbs and perioral area accompanied with muscles cramps or spasm sometimes; however, had impact on quality of life, daily functions, quality of sleep and lead to distress and depression. There is no drug to prevent peripheral neuropathy. Clinical observations reveal that acupuncture could decrease peripheral neuropathy, improve quality of life, and promote motivation of complete chemotherapy course.
Material and methods:
A total of 32 volunteers of patients with colorectal cancer will be recruited from the Chinese medicine or Western medicine clinics in China Medical University Hospital. These patients will be randomized to receive verum acupuncture or sham acupuncture treatment two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
Questionnaires, neurological examination and Von Frey Filament Test will be completed at baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
Predict results:
Investigators expect that the efficacy of verum acupuncture is superior to sham acupuncture in prevent or postpone occurrence of chemotherapy induced peripheral neuropathy and able to improve numbness, paresthesia, quality of life. The effectiveness of acupuncture can be detected by questionnaires, Von Frey Filament Test and neurological testing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
acupuncture, chemotherapy, peripheral neuropathy, randomized clinical trial, numbness
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
32 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Verum acupuncture
Arm Type
Experimental
Arm Description
16 patients will be randomized to receive verum acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
Arm Title
Sham acupuncture
Arm Type
Placebo Comparator
Arm Description
16 patients will be randomized to receive sham acupuncture two times biweekly, prior to beginning chemotherapy and the weeks that drugs administered, for 26 treatments in total.
Intervention Type
Other
Intervention Name(s)
Verum acupuncture
Intervention Description
Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a "de qi" sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a "de qi".
Primary Outcome Measure Information:
Title
Change from Baseline in NCV at 48weeks.
Time Frame
Baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
Title
Change from Baseline in Von frey filament test at 48weeks.
Time Frame
Baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
Secondary Outcome Measure Information:
Title
Change from Baseline in questionnaire - FACT/GOG-Ntx Subscale at 48weeks.
Time Frame
Baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
Title
Change from Baseline in questionnaire - FACT-G at 48weeks.
Time Frame
Baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
Title
Change from Baseline in questionnaire - Brief Pain Inventory Short Form at 48weeks.
Time Frame
Baseline, 12 and 24 weeks after initiation of intervention, 12 and 24 weeks after completion of acupuncture completion.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients were diagnosed as stage 3 colorectal cancer.
Patients are going to receive Oxaliplatin based chemotherapy.
Patients are willing to cooperate with physicians and completely receive chemotherapy.
Patients are willing to receive acupuncture treatments and follow-up assessments.
Adult volunteers with the ages of 20-70 years old.
ECOG Performance Status of 0, 1, or 2
Exclusion Criteria:
Current active treatments with chemotherapy, radiotherapy or tumor resection surgery in the past one month.
Having chemotherapy with neuropathic agents including taxane, platinum, vinca alkaloid, bortezimab, or thalidomide in the past six months.
Local infection at or near the acupuncture site is not suitable for acupuncture after physician examination.
Concurrent use of other alternative medicines such as herbal agents, high dose vitamins and minerals.
Known coagulopathy or taking anticoagulants.
Platelets < 50000/ul.
WBCs < 3000/ul.
Active CNS disease
Cardiac pacemaker.
Psychological or behavior disorder such as Schizophrenia.
Currently pregnant or breastfeeding women.
History of diabetic neuropathy or neuropathy related to HIV.
Previous acupuncture treatment for any indication within 30 days of enrollment.
Current medications that could affect symptoms related to CIPN.
Grade III lymphedema or more severe situation
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tzu-Liang Chen, M.D., MS.
Phone
+886-4-22052121
Ext
1639
Email
d1757@mail.cmuh.org.tw
First Name & Middle Initial & Last Name or Official Title & Degree
Ming-Cheng Huang, M.D
Phone
+886-4-22052121
Ext
1670
Email
mchuang1128@gmail.com
Facility Information:
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
404
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tzu-Liang Chen, M.D., MS.
Phone
+886-4-22052121
Ext
1639
Email
d1757@mail.cmuh.org.tw
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study
We'll reach out to this number within 24 hrs